- Procysbi (Raptor Pharmaceuticals): A Long Acting Cysteine For The Treatment Of Cystinosis
- Is AVEO's Tivozanib Any Better Than Placebo For The Treatment Of Renal Cell Carcinoma?
- Value Of Alexza's Staccato Platform Following Adasuve Approval
- Hemispherx's Ampligen For The Treatment Of Chronic Fatigue Syndrome: A Regulatory Conundrum
- Why Dynavax's Heplisav Is Likely To Be Approved: Impact On Future Vaccine Development
Richard Daifuku
ABOUT
Richard Daifuku MD-PhD has over 20 years experience in the biotechnology industry, with experience in multiple roles, including Chief Medical Officer, Chief Scientific Officer and Chief Executive Officer. He has multiple issued and pending patents for small molecules for the treatment of HIV and cancer. He is currently a consultant for Phase 1two3.
SNAPSHOT
- Description: Occasional investor. Trading frequency: Weekly
- Interests: Stocks - long
COMPANY
BLOG
Currently, there are no blog details for Richard Daifuku.
Book
Currently, there are no book details for Richard Daifuku.
Latest Comments
more »
Latest comments on Richard's Articles
LATEST ARTICLES & INSTAPOSTS
more »